|
APRIL'S BEST FEATURED EDITORIAL |
|
|
Takeda's Diversity Strategy Pays Off For Phase 3 Trial | By Dan Schell, Chief Editor, Clinical Leader | LaShell Robinson, head of global feasibility and trial equity at Takeda, explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics. |
|
|
|
Where Do We Stand With DCTs Heading Into 2025? | As told to Abby Proch, executive editor of guest columns, Clinical Leader | Clinical Leader asked familiar voices and new faces alike: “What’s left to say, to understand, or to do with DCTs (or elements thereof) in 2025?” |
|
|
APRIL'S BEST INDUSTRY INSIGHTS |
|
|
|
|
Navigating The Future Of Lab Developed Tests | By Ideagen | Explore the pivotal role of lab-developed tests (LDTs) in medical diagnostics, their growing regulatory scrutiny, and their future trajectory in modern healthcare to advance patient care. |
|
|
|
|
|
|
Connect With Clinical Leader: |
|
|
|